HUP0105302A3 - 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors, their use and process for their preparation - Google Patents
2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors, their use and process for their preparationInfo
- Publication number
- HUP0105302A3 HUP0105302A3 HU0105302A HUP0105302A HUP0105302A3 HU P0105302 A3 HUP0105302 A3 HU P0105302A3 HU 0105302 A HU0105302 A HU 0105302A HU P0105302 A HUP0105302 A HU P0105302A HU P0105302 A3 HUP0105302 A3 HU P0105302A3
- Authority
- HU
- Hungary
- Prior art keywords
- benzodiazepine
- tetrahydro
- preparation
- hydroxamic acid
- matrix metalloproteinase
- Prior art date
Links
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
- YWCKAVNWINYYFA-UHFFFAOYSA-N n-hydroxy-2,3,4,5-tetrahydro-1h-1,4-benzodiazepine-3-carboxamide Chemical compound C1NC(C(=O)NO)CNC2=CC=CC=C21 YWCKAVNWINYYFA-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23908099A | 1999-01-27 | 1999-01-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0105302A2 HUP0105302A2 (hu) | 2002-07-29 |
HUP0105302A3 true HUP0105302A3 (en) | 2002-09-30 |
Family
ID=22900512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0105302A HUP0105302A3 (en) | 1999-01-27 | 2000-01-27 | 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors, their use and process for their preparation |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1147095B1 (hu) |
JP (1) | JP2002535392A (hu) |
KR (1) | KR20010101730A (hu) |
CN (1) | CN1197849C (hu) |
AR (1) | AR022423A1 (hu) |
AT (1) | ATE273288T1 (hu) |
AU (1) | AU767039B2 (hu) |
BG (1) | BG105736A (hu) |
BR (1) | BR0007759A (hu) |
CA (1) | CA2356267A1 (hu) |
CZ (1) | CZ20012637A3 (hu) |
DE (1) | DE60012883T2 (hu) |
EA (1) | EA200100809A1 (hu) |
ES (1) | ES2223470T3 (hu) |
HU (1) | HUP0105302A3 (hu) |
ID (1) | ID29046A (hu) |
IL (1) | IL144168A0 (hu) |
NO (1) | NO20013675L (hu) |
NZ (1) | NZ511885A (hu) |
PL (1) | PL349025A1 (hu) |
PT (1) | PT1147095E (hu) |
SK (1) | SK10422001A3 (hu) |
TR (1) | TR200102131T2 (hu) |
WO (1) | WO2000044730A1 (hu) |
ZA (1) | ZA200104321B (hu) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2357110A1 (en) * | 2001-04-11 | 2002-10-11 | American Cyanamid Company | Method for the treatment of polycystic kidney disease |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US6770647B2 (en) | 2001-08-17 | 2004-08-03 | Bristol-Myers Squibb Pharma Company | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
EP1440057A1 (en) | 2001-11-01 | 2004-07-28 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US7488754B2 (en) | 2002-04-05 | 2009-02-10 | Wyeth | Method for the treatment of polycystic kidney disease |
EP1537098A1 (en) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company LLC | Monocyclic derivatives as matrix metalloproteinase inhibitors |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
EP1625334B9 (en) | 2003-05-21 | 2012-07-25 | Alexza Pharmaceuticals, Inc. | Percussively ignited self-contained heating unit |
DE602005023874D1 (de) * | 2004-07-21 | 2010-11-11 | Merck Serono Sa | Octahydropyrroloä2, 3, cüpyridinderivative und pharmazeutische verwendung damit |
EP1865001A1 (en) * | 2006-06-08 | 2007-12-12 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Specific protease inhibitors and their use in cancer therapy |
US20100226922A1 (en) * | 2006-06-08 | 2010-09-09 | Dorothea Maetzel | Specific protease inhibitors and their use in cancer therapy |
EP2121088B1 (en) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
FR2950056B1 (fr) | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
FR2950057B1 (fr) | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
EP2597084B1 (en) | 2010-07-08 | 2016-06-29 | Kaken Pharmaceutical Co., Ltd. | N-hydroxyformamide derivative and pharmaceutical containing same |
EP2617812B1 (en) * | 2010-09-17 | 2019-03-20 | The University of Tokyo | Composition for maintaining platelet function |
EP3860608A1 (en) | 2018-10-04 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
WO2021055817A1 (en) * | 2019-09-19 | 2021-03-25 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
MX9708026A (es) * | 1995-04-20 | 1997-11-29 | Pfizer | Derivados del acido arislfulfonil hidroxamico, composiciones que los contienen y uso de los mismos. |
ATE213232T1 (de) * | 1995-11-13 | 2002-02-15 | Hoechst Ag | Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren |
US5753653A (en) * | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
IL134816A (en) * | 1995-12-08 | 2003-02-12 | Agouron Pharma | Substituted diarylether sulfonic acids and their preparation |
CN1228773A (zh) * | 1996-08-28 | 1999-09-15 | 普罗克特和甘保尔公司 | 杂环金属蛋白酶抑制剂 |
BR9712085A (pt) * | 1996-08-28 | 2000-10-24 | Procter & Gamble | Inibidores de metaloprotease heterocìclicos |
NZ334251A (en) * | 1996-08-28 | 2000-11-24 | Procter & Gamble | 1,3-diheterocyclic metalloprotease inhibitors |
BR9907746A (pt) * | 1998-01-27 | 2000-10-17 | American Cyanamid Co | ácidos 2,3,4,5-tetraidro-1h[1,4]-benzodiazepina-3-hidroxâmic os como inibidores de matriz de metaloproteinase |
-
2000
- 2000-01-26 AR ARP000100323A patent/AR022423A1/es not_active Application Discontinuation
- 2000-01-27 SK SK1042-2001A patent/SK10422001A3/sk unknown
- 2000-01-27 PL PL00349025A patent/PL349025A1/xx not_active Application Discontinuation
- 2000-01-27 NZ NZ511885A patent/NZ511885A/xx unknown
- 2000-01-27 TR TR2001/02131T patent/TR200102131T2/xx unknown
- 2000-01-27 CZ CZ20012637A patent/CZ20012637A3/cs unknown
- 2000-01-27 ID IDW00200101465A patent/ID29046A/id unknown
- 2000-01-27 AT AT00909990T patent/ATE273288T1/de not_active IP Right Cessation
- 2000-01-27 HU HU0105302A patent/HUP0105302A3/hu unknown
- 2000-01-27 EA EA200100809A patent/EA200100809A1/ru unknown
- 2000-01-27 DE DE60012883T patent/DE60012883T2/de not_active Expired - Fee Related
- 2000-01-27 JP JP2000595986A patent/JP2002535392A/ja active Pending
- 2000-01-27 WO PCT/US2000/001991 patent/WO2000044730A1/en active IP Right Grant
- 2000-01-27 BR BR0007759-3A patent/BR0007759A/pt not_active IP Right Cessation
- 2000-01-27 EP EP00909990A patent/EP1147095B1/en not_active Expired - Lifetime
- 2000-01-27 PT PT00909990T patent/PT1147095E/pt unknown
- 2000-01-27 IL IL14416800A patent/IL144168A0/xx unknown
- 2000-01-27 CA CA002356267A patent/CA2356267A1/en not_active Abandoned
- 2000-01-27 ES ES00909990T patent/ES2223470T3/es not_active Expired - Lifetime
- 2000-01-27 KR KR1020017009430A patent/KR20010101730A/ko not_active Application Discontinuation
- 2000-01-27 AU AU32160/00A patent/AU767039B2/en not_active Ceased
- 2000-01-27 CN CNB008031355A patent/CN1197849C/zh not_active Expired - Fee Related
-
2001
- 2001-05-25 ZA ZA200104321A patent/ZA200104321B/en unknown
- 2001-07-26 NO NO20013675A patent/NO20013675L/no not_active Application Discontinuation
- 2001-07-26 BG BG105736A patent/BG105736A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CZ20012637A3 (cs) | 2002-04-17 |
HUP0105302A2 (hu) | 2002-07-29 |
NZ511885A (en) | 2003-06-30 |
DE60012883T2 (de) | 2005-08-25 |
CN1197849C (zh) | 2005-04-20 |
NO20013675L (no) | 2001-09-21 |
EA200100809A1 (ru) | 2002-02-28 |
AU3216000A (en) | 2000-08-18 |
DE60012883D1 (de) | 2004-09-16 |
WO2000044730A1 (en) | 2000-08-03 |
ZA200104321B (en) | 2002-08-26 |
TR200102131T2 (tr) | 2001-12-21 |
EP1147095B1 (en) | 2004-08-11 |
IL144168A0 (en) | 2002-05-23 |
ES2223470T3 (es) | 2005-03-01 |
JP2002535392A (ja) | 2002-10-22 |
KR20010101730A (ko) | 2001-11-14 |
BG105736A (en) | 2002-05-31 |
NO20013675D0 (no) | 2001-07-26 |
ID29046A (id) | 2001-07-26 |
SK10422001A3 (sk) | 2002-09-10 |
CN1337952A (zh) | 2002-02-27 |
AU767039B2 (en) | 2003-10-30 |
PT1147095E (pt) | 2004-12-31 |
ATE273288T1 (de) | 2004-08-15 |
PL349025A1 (en) | 2002-07-01 |
BR0007759A (pt) | 2001-11-13 |
CA2356267A1 (en) | 2000-08-03 |
EP1147095A1 (en) | 2001-10-24 |
AR022423A1 (es) | 2002-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0105302A3 (en) | 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors, their use and process for their preparation | |
HUP0201633A3 (en) | Alpha-aminosulphonyl-acetohydroxamic acid derivatives with metalloprotease inhibiting effect, preparation and use thereof | |
HUP0103376A3 (en) | New 3-aryl-2-hydroxypropionic acid derivative, pharmaceutical compositions containing it, process for their preparation and their use | |
EG24169A (en) | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | |
HUP0203669A3 (en) | Renin inhibitors, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0200807A3 (en) | Substituted propionic acid derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
ZA977700B (en) | Phosphinic acid amides as matrix metalloprotease inhibitors. | |
HUP0102766A3 (en) | Aminomethylcarboxylic acid derivatives, their pharmaceutical use and pharmaceutical compositions comprising them | |
AU4201799A (en) | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors | |
HK1045501A1 (zh) | 作為基質金屬蛋白酶抑制劑的異羥肟酸衍生物 | |
IL147216A0 (en) | Arylsulfonamido-substituted hydroxamic acid derivatives | |
AU6764400A (en) | Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors | |
IL129420A0 (en) | Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors | |
HK1020741A1 (en) | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | |
IL137162A0 (en) | 2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors | |
GB9916562D0 (en) | 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora | |
HRP970247A2 (en) | Substituted 4-arylbutric acid derivatives as matrix metalloprotease inhibitors | |
GB9929979D0 (en) | Hydroxamic acid derivatives | |
HUP0102447A3 (en) | Novel octahydro-6,10-dioxo-6h-pyridazino/1,2a//1,2/diazepin-1-carboxylic acid derivatives, preparation method and use for preparing therapeutically active compounds | |
GB9917593D0 (en) | Compound, composition, process and use | |
AU2002239438A1 (en) | 2,4-hexadienoic acid and derivatives as corrosion inhibitors | |
HUP0004510A3 (en) | Process for obtaining l-dihydroorotic acid and use thereof | |
AU7608100A (en) | 1-cyclohexene-1-carboxylic acid and 1-cyclohexene-1-carboxylates as neuraminidase inhibitors | |
AU7268800A (en) | Active agent preparation for veterinary use and method for the production thereof | |
AU2001252254A1 (en) | 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparationthereof and use thereof |